Results 161 to 170 of about 17,823 (170)

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer

Annals of Oncology, 2004
C P Belani, J R Jett, S Ramalingam
exaly  

Copper–topotecan complexation mediates drug accumulation into liposomes

Journal of Controlled Release, 2006
Marcel B Bally, Aman Taggar, Euan Ramsay
exaly  

A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients

Gynecologic Oncology, 2001
Howard D Homesley, L Vaccarello
exaly  

Development of a highly stable and targetable nanoliposomal formulation of topotecan

Journal of Controlled Release, 2010
Mark E Hayes, Daryl C Drummond, Dmitri B. Kirpotin   +2 more
exaly  

The Accumulation of Topotecan in 9L Glioma and in Brain Parenchyma with and without Dexamethasone Administration

Journal of Neuro-Oncology, 1999
W J Loos, J H M Schellens
exaly  

Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage

European Journal of Pharmacology, 2001
Jörg Wischhusen, Michael Weller, Ulrike Naumann   +2 more
exaly  

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy

Annals of Oncology, 2002
Jalid Sehouli, P Kläre, D Stengel
exaly  

Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

Gynecologic Oncology, 2005
David Scott Miller, John A Blessing, Jeanne M. Schilder   +2 more
exaly  

Tracking the cell cycle origins for escape from topotecan action by breast cancer cells

British Journal of Cancer, 2003
Paul J Smith, R J Errington
exaly  

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors

Cancer Chemotherapy and Pharmacology, 1995
Amar Gajjar, Clinton F Stewart, Sharyn D. Baker   +2 more
exaly